2029 Marketing Vaccine Virus 
Drug Discovery World
JANUARY 9, 2024
Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The first approvals of RSV vaccines (RSVpreF and RSVpreF3) targeted at infants and older adults mark a significant public health milestone.
Drug Discovery World
OCTOBER 4, 2022
There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. . BV-101 is an adeno- associated virus (AAV) gene therapy vector that simultaneously addresses the metabolic dysfunction of diseased neurons and contributes to the clearance of the mutant huntingtin protein.
Expert insights. Personalized for you.
173 
Let's personalize your content